TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20008708

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (1 mg)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (4 mg)
Number of subjects: 693

Group type: COMPARATOR
Intervention: Laser therapy (control group)
Number of subjects: 693
Study: 17161478

Group type: EXPERIMENTAL
Intervention: RT+AK-2123
Number of subjects: 333

Group type: COMPARATOR
Intervention: RT
Number of subjects: 333
Study: 15105032

Group type: EXPERIMENTAL
Intervention: 2 g beta‐hydroxy‐beta‐methylbutyrate, 5 g arginine, and 1.5 g lysine daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12033481

Group type: EXPERIMENTAL
Intervention: Involvement of practice nurses in the research project
Number of subjects: 100

Group type: COMPARATOR
Intervention: Age, sex, membership of an independent practitioner association (IPA), number of half days worked, number of GPs working in a practice
Number of subjects: 100
Study: 9876807

Group type: EXPERIMENTAL
Intervention: Intraperitoneal fluconazole 200 mg
Number of subjects: 5
Study: 7866603

Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg twice daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) 20 mg twice daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination of captopril and ISDN
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 2510288

Group type: EXPERIMENTAL
Intervention: rioprostil, 300 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: indomethacin, 75 mg and 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: baseline, no treatment
Number of subjects: 12
Study: 1130763

Group type: EXPERIMENTAL
Intervention: tobramycin
Number of subjects: 116

Group type: COMPARATOR
Intervention: gentamicin
Number of subjects: 116
Study: 31441500

Group type: EXPERIMENTAL
Intervention: Single-layer closure technique
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Double-layer closure technique
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 324
Study: 31381364

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - loading dose followed by continuous infusion for 48 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dextrose 5% (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 60
Study: 28548468

Group type: EXPERIMENTAL
Intervention: Direct training method
Number of subjects: 89

Group type: COMPARATOR
Intervention: Indirect training method
Number of subjects: 89
Study: 26129900

Group type: EXPERIMENTAL
Intervention: Dalitong granule (DG) 6 g 3 times daily
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at points Zusanli (ST36), Zhongwan (CV12), Neiguan (PC6), Taichong (LR3), Gongsun (SP4) twice daily
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Combined treatment of DG and EA
Number of subjects: 640

Group type: COMPARATOR
Intervention: Control group: 5 mg mosapride 3 times, 20 mg pantoprazole, and 25 mg amitriptyline twice daily
Number of subjects: 640
Study: 24057434

Group type: EXPERIMENTAL
Intervention: One-on-one advice from a community pharmacist along with a weight loss handbook for self-study
Number of subjects: 66

Group type: COMPARATOR
Intervention: Group counselling from the PCU staff as usual
Number of subjects: 66
Study: 22097156

Group type: EXPERIMENTAL
Intervention: Propranolol (2 mg/kg per day or 3 mg/kg per day)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 213

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 213
Study: 17895911

Group type: EXPERIMENTAL
Intervention: Flexible administration of micronutrient Sprinkles over 4 months
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Flexible administration of micronutrient Sprinkles over 3 months
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Daily administration of micronutrient Sprinkles over 2 months
Number of subjects: 362
Study: 16432275

Group type: EXPERIMENTAL
Intervention: Midazolam plasma concentrations
Number of subjects: 86

Group type: COMPARATOR
Intervention: 1‐OH MDZ to midazolam plasma concentration ratios
Number of subjects: 86
Study: 12975660

Group type: EXPERIMENTAL
Intervention: TAC (docetaxel, doxorubicin, cyclophosphamide) chemotherapy (75/50/500 mg/m2 6x q3wk)
Number of subjects: 61

Group type: COMPARATOR
Intervention: FAC (5‐fluorouracil, doxorubicin, cyclophosphamide) chemotherapy (500/50/500 mg/m2 6x q3wk)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: TAC
Number of subjects: 61
Study: 11079643

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg daily for four weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sodium nitroprusside and monomethyl arginine
Number of subjects: 9
Study: 8947886

Group type: COMPARATOR
Intervention: Interferon-alpha 2b (r-IFN-alpha 2b) at doses of 5, 2.5, or 1.25 million units (MU) daily for a minimum of 14 days prior to transplantation and continuing for 42 days post-transplantation.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Interferon-alpha 2b (r-IFN-alpha 2b) treatment.
Number of subjects: 28
Study: 1329219

Group type: EXPERIMENTAL
Intervention: Carboplatin plus vincristine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carboplatin plus vincristine plus ifosfamide
Number of subjects: 0
Study: 4078182

Group type: EXPERIMENTAL
Intervention: High-stimulation colored letters
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-stimulation black letters
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group performance
Number of subjects: 32
Study: 30488222

Group type: EXPERIMENTAL
Intervention: 10 mg amisulpride
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318

Group type: COMPARATOR
Intervention: Three-drug control
Number of subjects: 318
Study: 30227000

Group type: EXPERIMENTAL
Intervention: Robustness training for high-risk athletes (n = 33)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Robustness training for low-risk athletes (n = 33)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (n = 54)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: High-risk group (n = 33)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Low-risk group (n = 33)
Number of subjects: 125
Study: 27870477

Group type: EXPERIMENTAL
Intervention: Noribogaine 60 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Noribogaine 120 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Noribogaine 180 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 24993856

Group type: EXPERIMENTAL
Intervention: Dual-phase calcium silicate/phosphate gel combined with calcium silicate/phosphate toothpaste (TG+TP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo TG+TP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo TG+marketed 1450 ppmF toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo TG+placebo TP
Number of subjects: 0
Study: 23215984

Group type: EXPERIMENTAL
Intervention: Positive relationships with mothers or other supportive adults
Number of subjects: 30
Study: 20157666

Group type: EXPERIMENTAL
Intervention: RelyX Unicem with prior enamel acid etching (Etch)
Number of subjects: 31

Group type: COMPARATOR
Intervention: RelyX Unicem without prior enamel acid etching (Non-etch)
Number of subjects: 31
Study: 17287409

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Untreated group (UTRG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both groups (TRG and UTRG)
Number of subjects: 34
Study: 16236891

Group type: EXPERIMENTAL
Intervention: rhDNase (dornase alfa)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 12161765

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra) 25, 50 or 100 mg
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 9883302

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.03% (42 mcg per nostril) administered three times daily plus terfenadine 60 mg administered twice daily
Number of subjects: 205

Group type: COMPARATOR
Intervention: Vehicle nasal spray plus terfenadine 60 mg administered twice daily
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray plus terfenadine
Number of subjects: 205

Group type: COMPARATOR
Intervention: Vehicle nasal spray plus terfenadine
Number of subjects: 205
Study: 7543494

Group type: EXPERIMENTAL
Intervention: rhIGF‐I administration
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 2087049

Group type: EXPERIMENTAL
Intervention: RBA with adrenaline (5 ml of a lidocaine‐bupivacaine mixture with hyaluronidase, after‐mixing concentration 1:500,000)
Number of subjects: 80

Group type: COMPARATOR
Intervention: RBA without adrenaline (5 ml of a lidocaine‐bupivacaine mixture with hyaluronidase)
Number of subjects: 80
Study: 650879

Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/ml and Diazepam 0.1 mg/ml administered by intravenous drip at a rate of 0.1 ml/kg/min for the first 5 min and 0.017 ml/kg/min for the next 15 min.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Droperidol 0.125 mg/kg given intravenously before administration of ketamine-diazepam solution.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nitrous-oxide and oxygen anesthesia (control group).
Number of subjects: 30
Study: 31810829

Group type: EXPERIMENTAL
Intervention: Intervention group (mobile health-based program with weekly automated assessment and behavior change calls, structured email feedback to caregivers, and fax alerts to clinicians)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Intervention group (specifically for pulmonary diagnoses)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Overall intervention group
Number of subjects: 283
Study: 30649918

Group type: EXPERIMENTAL
Intervention: 12-week exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27858951

Group type: EXPERIMENTAL
Intervention: Occupational therapy fall reduction home visit program (IG)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Well-wishing visit from a research assistant (CG)
Number of subjects: 311
Study: 25560448

Group type: EXPERIMENTAL
Intervention: WE CARE intervention
Number of subjects: 336
Study: 23558806

Group type: EXPERIMENTAL
Intervention: 6-week training on cycloergometer, 3 times a week, at 70-80% of max tolerated heart rate (HR) (training group, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 100
Study: 21325226

Group type: EXPERIMENTAL
Intervention: Probiotic culture (FloraMax, IVS‐Wynco LLC) administered via oral gavage 1 hour post SH challenge.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 19944358

Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5mg) plus folic acid (5mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo plus folic acid (5mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined outcome (death, myocardial infarction, stroke, hospitalization, need for myocardial revascularization)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 50
Study: 16765801

Group type: EXPERIMENTAL
Intervention: Bilateral cataract surgery on the same day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cataract surgery in 1 eye at a time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups after surgery
Number of subjects: 0
Study: 14970962

Group type: EXPERIMENTAL
Intervention: modified constraint-induced movement therapy (mCIMT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: regular therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: control (no therapy)
Number of subjects: 17
Study: 11779013

Group type: EXPERIMENTAL
Intervention: CT fluoroscopy combined with fluoroscopy (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoroscopy alone (Group B)
Number of subjects: 40
Study: 9256515

Group type: EXPERIMENTAL
Intervention: Direct treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Direct observation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Indirect observation
Number of subjects: 46
Study: 8498838

Group type: EXPERIMENTAL
Intervention: Neurosurgical excision plus radiotherapy (whole brain radiotherapy, 2 fractions per day of 2 Gy for a total of 40 Gy)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Neurosurgical excision plus radiotherapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 63
Study: 3481039

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HDMTX-vincristine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidrug regimens containing HDMTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regimens excluding HDMTX
Number of subjects: 0
Study: 30582880

Group type: EXPERIMENTAL
Intervention: Chitosan brush treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Titanium curettes treatment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 11
Study: 29985375

Group type: EXPERIMENTAL
Intervention: Autogenic training (AT) based psychotherapy
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control group (no psychotherapy)
Number of subjects: 325
Study: 25603363

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) supplementation (500 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 25231564

Group type: EXPERIMENTAL
Intervention: Potentilla anserina (verum)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 22385121

Group type: EXPERIMENTAL
Intervention: 5% permethrin cream (twice application with a 1-week interval)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Oral ivermectin (single dose)
Number of subjects: 242
Study: 20123835

Group type: EXPERIMENTAL
Intervention: Systematic use of a transparent plastic collector bag
Number of subjects: 25381

Group type: COMPARATOR
Intervention: Visual assessment of postpartum blood loss (control group)
Number of subjects: 25381
Study: 18278302

Group type: EXPERIMENTAL
Intervention: 10% hydrofluoric acid application for 2 min plus rinsing and drying, followed by silane application for 30 s (G1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Airborne particle abrasion with 30 microm silica oxide particles (CoJet‐Sand) for 20 s, followed by silane application for 5 min (G2)
Number of subjects: 10
Study: 16159829

Group type: EXPERIMENTAL
Intervention: Arterial conduit (right internal thoracic or radial artery)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Great saphenous vein graft (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Right internal thoracic artery
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saphenous vein grafts
Number of subjects: 120
Study: 11837056

Group type: EXPERIMENTAL
Intervention: Back school with peer support (treatment group, n = 47)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Back school without peer support (control group, n = 46)
Number of subjects: 108
Study: 10023644

Group type: EXPERIMENTAL
Intervention: 20% albumin infusion, 100 mL/d for 7 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: No intervention (disease-control group)
Number of subjects: 22
Study: 7601922

Group type: EXPERIMENTAL
Intervention: Surrogate endpoints
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Mean probing depth
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Mean probing attachment level
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Plaque index
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Surrogate endpoints based on re-entry surgery
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Microbiological surrogate endpoints
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Multiple surrogate endpoints
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Tooth loss
Number of subjects: 82
Study: 2364916

Group type: EXPERIMENTAL
Intervention: Stress-inducing horror films
Number of subjects: 12

Group type: COMPARATOR
Intervention: Romantic family films (control)
Number of subjects: 12
Study: 520164

Group type: EXPERIMENTAL
Intervention: Sulprostone (i.m. application for induction of early abortion before the 6th week of pregnancy)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Sulprostone (i.v. drip for termination of intact and disturbed pregnancies beyond the first trimester)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Systemic forms of administration (i.v. and i.m.)
Number of subjects: 479
Study: 30973207

Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg/day
Number of subjects: 505

Group type: COMPARATOR
Intervention: Nifedipine-GITS 30-60 mg/day
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Amlodipine (after missing a dose)
Number of subjects: 505
Study: 29121269

Group type: EXPERIMENTAL
Intervention: FSH dose of 100 IU/day
Number of subjects: 521

Group type: COMPARATOR
Intervention: FSH dose of 150 IU/day
Number of subjects: 521
Study: 26508675

Group type: EXPERIMENTAL
Intervention: Sitagliptin at 50mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glimepiride at 1mg/day
Number of subjects: 30
Study: 23374559

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (daily for 6 months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (daily for 6 months)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 20093966

Group type: EXPERIMENTAL
Intervention: Postactivation potentiation (PAP) through a 10‐second maximal voluntary contraction (MVC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (without MVC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Electromyographic signals during concentric contractions
Number of subjects: 9
Study: 19383582

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (800 mg/day orally) for 5 days before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no pentoxifylline)
Number of subjects: 40
Study: 17223540

Group type: EXPERIMENTAL
Intervention: HPV testing with liquid-based cytology and referral for colposcopy
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 1242
Study: 15499270

Group type: EXPERIMENTAL
Intervention: Nonpreserved diclofenac (Dicloabak)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiomersal-preserved diclofenac
Number of subjects: 40
Study: 11484951

Group type: EXPERIMENTAL
Intervention: Mitoxantrone and prednisone (M + P)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Prednisone alone (P)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: PSA responders (from both groups)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: PSA responders
Number of subjects: 161
Study: 9538598

Group type: EXPERIMENTAL
Intervention: Alpha-amylase added to maize-based weaning foods
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditionally prepared Amylase-Rich Foods (ARF)
Number of subjects: 30
Study: 7846351

Group type: EXPERIMENTAL
Intervention: cisplatin + navelbine
Number of subjects: 612

Group type: COMPARATOR
Intervention: cisplatin + vindesine
Number of subjects: 612

Group type: COMPARATOR
Intervention: navelbine
Number of subjects: 612
Study: 3381754

Group type: EXPERIMENTAL
Intervention: Dipyridamole-exercise stress test
Number of subjects: 43

Group type: COMPARATOR
Intervention: Exercise stress test
Number of subjects: 43
Study: 31566064

Group type: EXPERIMENTAL
Intervention: Cantonese vowel length contrasts perception task (AXB discrimination task)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: L2 English perception
Number of subjects: 3
Study: 29888582

Group type: EXPERIMENTAL
Intervention: Combined treatment (electroacupuncture, acupoint-injection, fire-needle)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (electroacupuncture alone)
Number of subjects: 100
Study: 27993811

Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy with gemcitabine, dexamethasone, cisplatin (GDP) or dexamethasone, cytarabine, cisplatin (DHAP) followed by autologous stem cell transplantation (ASCT)
Number of subjects: 619
Study: 24961994

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise (PRE)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Modified Fitness Counts (mFC)
Number of subjects: 38
Study: 23422097

Group type: EXPERIMENTAL
Intervention: Combined subfascial endoscopic perforator surgery (SEPS) and endovenous laser treatment (EVLT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Traditional GSV phlebectomy
Number of subjects: 83
Study: 20440528

Group type: EXPERIMENTAL
Intervention: 5 mg of bovine type II collagen (bCII)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5 mg of bovine type II collagen (bCII)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05 mg of bovine type II collagen (bCII)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18328842

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention (PCI)
Number of subjects: 0
Study: 17009230

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with MTX plus etanercept
Number of subjects: 0
Study: 12910510

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 153
Study: 10921554

Group type: EXPERIMENTAL
Intervention: Oxidized‐raffinose cross‐linked human hemoglobin (Hemolink) at doses of 0.025-0.6 g/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Oxidized‐raffinose cross‐linked human hemoglobin (Hemolink)
Number of subjects: 42
Study: 8612381

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of terfenadine (60 mg twice a day) with grapefruit juice (240 ml) for 7 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Delayed administration of terfenadine (60 mg twice a day) with grapefruit juice (240 ml) 2 hours after terfenadine for 7 days
Number of subjects: 12